RxDoctor Payments Data

Glenda Denherder, APRN

Psychiatric/Mental Health · Sioux City, IANPI 1477596450

Payments from drug & device makers

$3,863in general payments, 2019–2025

Across 224 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$469
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$429
  • AbbVie$412
  • Otsuka America Pharmaceutical, Inc.$403
  • Johnson & Johnson$369
  • Teva Pharmaceuticals USA, Inc.$343
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,80799%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,863 in reported general payments places this provider in the 85th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$31,052
Medicare patients
64
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$93,420
VraylarCariprazine Hcl54$72,202
RexultiBrexpiprazole26$40,454
TrintellixVortioxetine Hydrobromide21$10,032
BelsomraSuvorexant14$9,074
Clozapine17$3,332
Desvenlafaxine Succinate ErDesvenlafaxine Succinate45$2,587
Vilazodone Hcl40$2,545
Quetiapine Fumarate102$1,855
Aripiprazole49$1,771
Bupropion XlBupropion Hcl99$1,483
Duloxetine Hcl110$1,462
Atomoxetine Hcl14$1,450
Ziprasidone Hcl28$1,447
Mirtazapine38$1,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$343$93,42011 claims
AbbVieVraylar$412$72,20254 claims
Otsuka America Pharmaceutical, Inc.Rexulti$403$40,45426 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$88$10,03221 claims
MerckBelsomra$62$9,07414 claims
Almatica Pharma LLCSertraline Hcl$46$40950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →